Search Results
Your search for ,itS matches 8761 pages
Showing 6051 - 6100Ed Sauter, MD, PhD, Named Director of Breast Surgery Program at Hartford HealthCare Cancer Institute
Hartford HealthCare Cancer Institute announced the appointment of Ed Sauter, MD, PhD, as Director of the Breast Surgery Program at the Hartford HealthCare Cancer Institute (HHCCI). He will lead the breast surgery programs at each of the Institute’s five cancer centers. Dr. Sauter is joining the...
Friends of Cancer Research Encourages FDA to Modernize and Consolidate
“In order to take advantage of today’s advancements in science, drug development, and patient treatment, the U.S. Food and Drug Administration’s (FDA’s) structure needs reorganization to focus its resources and ensure the best outcomes for patients. Friends of Cancer Research (Friends) proposes...
Raising Awareness of Medullary Thyroid Carcinoma
I’m used to having bumps and cysts pop up on my body, so when I felt a lump on the front of my throat, just below my Adam’s apple, I brushed it off. But when it was still there 6 months later, I became concerned and decided to see an ear, nose, and throat specialist. He performed a fine-needle...
2016–2017 HOPA President Sarah Scarpace, PharmD, MPH, BCOP, Takes Office
The Hematology/Oncology Pharmacy Association (HOPA) has elected Sarah Scarpace, PharmD, MPH, BCOP, to serve as President for the 2016–2017 term. Dr. Scarpace recently took office at the 12th HOPA Annual Conference, held March 16–19 in Atlanta, Georgia. Dr. Scarpace has served as President-Elect...
Susannah Koontz, PharmD, BCOP, FHOPA, Named HOPA President-Elect for 2016–2017 Term
Susannah Koontz, PharmD, BCOP, FHOPA, took office as President-Elect of the Hematology/Oncology Pharmacy Association (HOPA) at the recent 12th HOPA Annual Conference, held March 16–19 in Atlanta, Georgia. Dr. Koontz will serve as President-Elect for the 2016–2017 term and assume the office of...
Radiation: Myths, Facts, Dangers and Benefits
For many, the word “radiation” conjures up images of mushroom clouds and the nightmarish nuclear disaster at Chernobyl. It also brings to mind those pesky dental x-rays and lifesaving cancer treatments. However, to most people, radiation is a mysterious invisible power to be feared and embraced...
Immunotherapy Could Be the Wave of the Future, but Problems and Challenges Cannot Be Ignored
Immunotherapy is on its way. A few agents have already been approved: ipilimumab (Yervoy) in 2011 for melanoma; nivolumab (Opdivo) in 2015 for non–small cell lung cancer (NSCLC) and then later that year for renal cell carcinoma; and pembrolizumab (Keytruda) for NSCLC. In addition, many clinical...
Supportive Care in the Older Adult With Cancer: What You Need to Know
The median age of patients at the first diagnosis of cancer in the United States is 65 years, and the majority of patients with cancer are older adults.1 As we have learned from previous articles in this series, older patients with cancer require more complex care. Older adults are more likely to...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians.1,2 The guideline recommendations were formulated by a multidisciplinary expert work group and are based...
Leena Gandhi, MD, PhD, Named Director of Thoracic Medical Oncology at NYU Langone’s Perlmutter Cancer Center
New York University (NYU) Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as Director of Thoracic Medical Oncology at its Laura and Isaac Perlmutter Cancer Center. In this new role, Dr. Gandhi will be tasked with building a robust program in lung...
Drug Prices and Value: Finding Middle Ground
The advent of targeted therapies along with complex personalized treatment regimens has added many effective tools to the oncology armamentarium. But progress has a price tag. Although the oncology community needs new drugs, there is growing concern that the price of many newer compounds is...
2016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care
Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...
Meet W. Charles Penley, MD, FASCO
A Partner at Tennessee Oncology, PLLC, W. Charles Penley, MD, FASCO, has been an ASCO member since 1988. He has served on the Conquer Cancer Foundation Board of Directors since 2005 and currently holds the role of Immediate Past Chair. What led you to oncology? WCP: While it may sound silly to say ...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. We chose Boswellia for this issue because of its increasing use by patients with cancer....
Blue Ribbon Panel to Help Guide National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer ...
Pembrolizumab Looks Promising in Multiple Myeloma
Monoclonal antibodies targeting the programmed cell death protein (PD-1) receptor look promising in multiple myeloma, according to early reports presented at the 2015 ASH Annual Meeting and Exposition. Early signs of activity in heavily pretreated patients may indicate that, as in solid tumors,...
Neoadjuvant Endocrine Therapy Vastly Underutilized by U.S. Clinicians
Neoadjuvant endocrine therapy in the management of breast cancer is woefully underutilized by U.S. clinicians, according to advocates of this approach who made their case at the 2016 Miami Breast Cancer Conference.1 In postmenopausal women with estrogen receptor–rich tumors, neoadjuvant endocrine...
ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention
As reported in the Journal of Clinical Oncology by Bailey et al, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States. In the United States, HPV is estimated to cause approximately 99.7% of cervical cancers, 60% of...
Physicians as Champions for Quality Improvement
Interest in quality measurement and improvement was once primarily a concern of regulators, insurers, and consumer advocates. Today, quality improvement is front and center in health care—a continuous mission requiring the efforts of everyone on the health-care team. At the recent ASCO Quality Care ...
Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma
Although high-dose chemotherapy plus autologous transplantation has been a standard of care in the treatment of younger patients with newly diagnosed multiple myeloma, the advent of effective novel agents for the cancer over the past 15 years has raised the question of whether transplantation, with ...
Novel Strategies Emerging for Triple-Negative Breast Cancer
Compelling hypotheses are emerging about the mechanisms driving triple-negative breast cancer, and they are driving drug development in this area, according to Joyce O’Shaughnessy, MD, Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center. She is also Medical...
AACR 2016: Palbociclib Shows Antiproliferative Activity in Early-Stage Breast Cancer
The molecularly targeted therapeutic palbociclib (Ibrance) was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who received no prior therapy, according to data from a phase II clinical trial presented by Arnedos et al at the 2016 AACR...
AACR 2016: MammaPrint Genetic Test Can Reduce Use of Adjuvant Chemotherapy Among Early-Stage Breast Cancer Patients
Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biologic criteria, the MammaPrint genetic test identified a large group of patients for whom 5-year distant metastasis–free survival was equally good whether or not they ...
AACR 2016: LOXO-101 Shows Continued Promise in Patients Whose Tumors Had NTRK Gene Fusions
The investigational drug LOXO-101, which selectively targets a family of proteins called neurotrophic tyrosine kinase receptors (NTRKs), produced significant tumor regression in patients whose tumors had NTRK gene fusions, according to data from a phase I clinical trial presented by Hong et al at...
ELCC 2016: Immunotherapy With Live Bacterium Improves Response Rate in Malignant Pleural Mesothelioma
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and a 59% response rate in patients with malignant pleural mesothelioma, according to the results of a phase Ib trial presented by Jahan et al April 14 (Abstract 208O_PR) at the European Lung...
The Parker Foundation Launches the Parker Institute for Cancer Immunotherapy With a $250 Million Grant
On April 13, The Parker Foundation announced a $250 million grant to launch the Parker Institute for Cancer Immunotherapy, a collaboration between scientists, clinicians, and industry partners to lead an unprecedented cancer immunotherapy research effort. The gift is the largest single contribution ...
FDA Accepts Supplemental Biologics License Application for Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer, Grants Priority Review
Merck today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), a monoclonal antibody and anti–programmed cell death 1 (PD-1) therapy, for the treatment of...
Acupuncture Improves Hot Flashes in Women With Breast Cancer in Italian Trial
In an Italian trial reported in the Journal of Clinical Oncology, Lesi et al found that the addition of acupuncture to enhanced self-care improved hot flashes, climacteric symptoms, and quality-of-life measures in women with breast cancer. Study Details In the trial, 190 women were randomized to...
Shorter Delays Between Diagnosis, Surgery, and Chemotherapy Initiation May Improve Survival in Breast Cancer
The survival benefits of reducing the time to surgery following a diagnosis of breast cancer, and time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a...
p53- and Mevalonate Pathway–Driven Cancers Require Cell-Signaling Protein Arf6 for Metastasis and Drug Resistance
A metabolic pathway that is upregulated in certain breast cancers promotes the disease's progression by activating a cell-signaling protein called Arf6, according to findings published by Hashimoto et al in the Journal of Cell Biology. The study, conducted by a team of researchers at Hokkaido...
sFRP2 in Aged Melanoma Tumor Cells Drives Metastasis and Therapy Resistance
Cancer risk increases with one's age as accumulated damage to our cells and chronic inflammation occur over time. Now, an international team of scientists led by The Wistar Institute has shown that aged tumor cells in melanoma behave differently from younger tumor cells, according to study results...
Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older
A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was published in the Journal of Oncology Practice. The corresponding author...
Sadik Esener, PhD, Selected to Lead OHSU’s Large-Scale Early Cancer Detection Initiative
Sadik Esener, PhD, has been recruited to the Oregon Health & Science University (OHSU) Knight Cancer Institute to lead the first large-scale early cancer detection program of its kind. Dr. Esener will be the Director of the Institute’s Center for Early Detection Research and has been awarded...
A Political Activist Challenges the Drug Approval Process and the U.S. Government
The U.S. Food and Drug Administration’s (FDA’s) primary concern in the drug approval process is to ensure that the drug is safe and effective. For the past several decades, the advocacy groups have vociferously painted the agency as a stodgy bureaucracy that prevents desperate patients access to...
Things May Not Be What They Seem: Are Old Cancer Treatment Theories New Again?
The adage “you can’t judge a book by its cover,” is true, but authors still need to be aware of the importance of first impressions. The title of science writer Travis Christofferson’s book Tripping Over the Truth: The Return of the Metabolic Theory of Cancer Illuminates a New and Hopeful Path to ...
Michael J. Birrer, MD, PhD, Named Recipient of the 2016 Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher
The Claudia Cohen Research Foundation and the Foundation for Women’s Cancer announced Michael J. Birrer, MD, PhD, as the 2016 recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. The $50,000 prize was presented at the Society of Gynecologic...
Joan Massagué, PhD, to Receive 2016 Pezcoller Foundation–AACR International Award for Cancer Research
The 2016 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research will be presented to Joan Massagué, PhD, Director of the Sloan Kettering Institute and Alfred P. Sloan Chair at Memorial Sloan Kettering Cancer Center in New York, at the AACR...
Samuel Waxman Cancer Research Foundation Appoints Robert Hromas, MD, to Its Scientific Advisory Board
The Samuel Waxman Cancer Research Foundation (SWCRF) announced the addition of cancer researcher Robert Hromas, MD, Chair of Medicine at University of Florida Health, to its scientific advisory board (SAB). Dr. Hromas, who continues his position at the University of Florida Health, will join his...
Selected Abstracts From 2015 ASH Annual Meeting: Part 4
Here is the final installment of selected abstracts from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. For other selected abstracts...
Providing Perspective on Pressing Economic Issues Facing Cancer Care—Now and in the Future
CANCERSCAPE, the 2016 Annual Meeting of the Association of Community Cancer Centers (ACCC), provided a forum for about 300 attendees to gain insight into the complexities of oncology treatment, where “clinical advances, policy mandates, and value-based payment reform intersect.” Of particular...
Understanding and Preparing for MACRA
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed in April 2015, introducing comprehensive changes to how Medicare pays physicians for services. As the policies passed in MACRA are rolled out over the coming years, they will profoundly impact reimbursement and care...
Conquer Cancer Foundation Honors 74 Oncologists for Contributions to Genitourinary Cancer, Cancer Survivorship, Gastrointestinal Cancer, and Quality Care Research
The Conquer Cancer Foundation of ASCO is pleased to announce the recipients of its 2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancer, Genitourinary Cancer, Cancer Survivorship, and Quality Care. The following 74 young investigators, recognized for the scientific merit...
NCI Announces Blue Ribbon Panel to Help Guide Vice President Biden’s National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National...
New Commission on Cancer Standards Clarifies and Emphasizes Process, Quality, Data Reporting, and More
The 2016 edition of the Commission on Cancer’s accreditation standards manual clarifies and provides additional information in many areas and raises the bar for compliance in some, including psychosocial distress screening, survivorship care, data reporting, and activities in prevention and...
Outcome Measures in Quality and Identifying High-Quality Practice
At this year’s ASCO Quality Care Symposium, Craig Earle, MD, MSc, of the Ontario Institute for Cancer Research, used Donabedian’s Triad—structure, process, and outcome—to set the stage for his presentation on the science of quality. “The theory behind Donabedian’s Triad is that structure...
Experts Consider What It Means to Improve Quality of Care in an Era of Increasing Reliance on Targeted Therapies
Precision medicine is judged according to different values across the multiple stakeholders involved in cancer care. At this year’s Quality Care Symposium, presenters from different sectors of oncology addressed a central question: How do we assess quality in the age of precision medicine?1,2 Right ...
Jeffrey Fowler, MD, Begins Presidency of Society of Gynecologic Oncology
Jeffrey Fowler, MD, John G. Boutselis Chair in Gynecologic Oncology and Professor and Vice-Chair of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center, started his 1-year term as the 48th President of the Society of Gynecologic Oncology (SGO) at the conclusion of the...
Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO
Clifford A. Hudis, MD, FACP, Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at Memorial Sloan Kettering Cancer Center (MSKCC), and Professor of Medicine at Weill Cornell Medical College, has been named the next Chief Executive Officer...
Throwing Out the Baby With the Bathwater: A Critical Appraisal of the USPSTF Recommendation Against Screening for Prostate Cancer
In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation against routine screening for prostate cancer.1,2 The grade D recommendation was considered controversial at the time, and remains so now, because many stakeholders have weighed the same body of evidence and come to...
ENDO 2016: BPA Changes Fetal Development of the Mammary Gland, Can Raise Breast Cancer Risk
A new culture system that tests the role of chemical exposure on the developing mammary gland has found that bisphenol A (BPA) directly affects the mammary gland of mouse embryos. The study results, presented by Speroni et al Friday, April 1, at the Endocrine Society's Annual Meeting in Boston...
